Dare Bioscience (DARE) Notes Payables (2013 - 2020)

Dare Bioscience's (DARE) quarterly Notes Payables came in at $367285.0 in Q4 2020, little changed on a QoQ basis from $367285.0 in Q3 2020.

Dare Bioscience (DARE) Notes Payables (2013 - 2020) Analysis & Trends

Dare Bioscience (DARE) has 4 years of Notes Payables data on file, last reported at $367285.0 in Q4 2020.

Quarterly Notes Payables changed N/A year-over-year to $367285.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $367285.0 (changed N/A YoY) and the FY2020 annual result came in at $367285.0, changed N/A from the prior year.
Notes Payables held at $367285.0 in Q4 2020, from $367285.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $697500.0 in Q4 2016 to a low of $367285.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Dare Bioscience	12.36 Mn	-256,055.23	-132,343.00

Download Data